Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis

AIMS: To develop a population pharmacokinetic model for pyrimethamine (PYR) and sulfadoxine (SDX) in children with congenital toxoplasmosis. METHODS: Children were treated with PYR (1.25 mg kg(−1)) and SDX (25 mg kg(−1)) (Fansidar®) plus folinic acid (Lederfoline® 5 mg). Plasma concentrations, avail...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Trenque, T, Simon, N, Villena, I, Chemla, C, Quereux, C, Leroux, B, Jaussaud, R, Rémy, G, Dupouy, D, Millart, H, Pinon, J-M, Urien, S
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2004
Assuntos:
Pharmacokinetics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1884514/
https://ncbi.nlm.nih.gov/pubmed/15151519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2004.02077.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados